Status:
COMPLETED
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
Lead Sponsor:
Pfizer
Conditions:
Thyroid Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine
Detailed Description
Additional study details: assess safety and efficacy
Eligibility Criteria
Inclusion
- Radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer
- At least 1 measurable target lesion, as defined by RECIST
Exclusion
- Thyroid lymphoma
- Previous treatment with anti-angiogenesis agents
- No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism within 12 months prior.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00389441
Start Date
December 1 2006
End Date
September 1 2012
Last Update
November 25 2013
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Orange, California, United States, 92868
2
Pfizer Investigational Site
Aurora, Colorado, United States, 80010
3
Pfizer Investigational Site
Tampa, Florida, United States, 33612
4
Pfizer Investigational Site
Chicago, Illinois, United States, 60637-1470